Time to omit interim CT imaging during frontline chemoimmunotherapy for patients with follicular lymphoma?

References

• Borchmann P, Goergen H, Kobe C, et al. PET-guided treatment in patients with advanced-stage hodgkin’s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the german hodgkin study group. Lancet. 2017;390(10114):2790–2802.
   PubMed Web of Science ®Google Scholar
• Johnson P, Federico M, Kirkwood A, et al. Adapted treatment guided by interim PET-CT scan in advanced hodgkin’s lymphoma. N Engl J Med. 2016;374(25):2419–2429.
   PubMed Web of Science ®Google Scholar
• Radford J, Illidge T, Counsell N, et al. Results of a trial of PET-directed therapy for early-stage hodgkin’s lymphoma. N Engl J Med. 2015;372(17):1598–1607.
   PubMed Web of Science ®Google Scholar
• Mamot C, Klingbiel D, Hitz F, et al. Final results of a prospective evaluation of the predictive value of interim positron emission tomography in patients with diffuse large B-Cell lymphoma treated with R-CHOP-14 (SAKK 38/07). J Clin Oncol. 2015;33(23):2523–2529.
   PubMed Web of Science ®Google Scholar
• Mikhaeel NG, Cunningham D, Counsell N, et al. FDG-PET/CT after two cycles of R-CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome - final result of a UK national cancer research institute prospective study. Br J Haematol. 2021;192(3):504–513.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Ghielmini M, Rule S, ESMO Guidelines Committee. Electronic address: [email protected], et al. Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(3):298–308.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Fisher RI, Barrington SF, United Kingdom National Cancer Research Institute, et al. Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-Hodgkin lymphoma: the lugano classification. J Clin Oncol. 2014;32(27):3059–3068.
   PubMed Web of Science ®Google Scholar
• Le Dortz L, De Guibert S, Bayat S, et al. Diagnostic and prognostic impact of 18F-FDG PET/CT in follicular lymphoma. Eur J Nucl Med Mol Imaging. 2010;37(12):2307–2314.
   PubMed Web of Science ®Google Scholar
• Luminari S, Biasoli I, Arcaini L, et al. The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the fondazione italiana linfomi. Ann Oncol. 2013;24(8):2108–2112.
   PubMed Web of Science ®Google Scholar
• Trotman J, Luminari S, Boussetta S, et al. Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of Central scan review in three multicentre studies. Lancet Haematol. 2014;1(1):e17-27–e27.
   PubMed Web of Science ®Google Scholar
• Trotman J, Barrington SF, Belada D, et al. Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial. Lancet Oncol. 2018;19(11):1530–1542.
   PubMed Web of Science ®Google Scholar
• Bishu S, Quigley JM, Bishu SR, et al. Predictive value and diagnostic accuracy of F-18-fluoro-deoxy-glucose positron emission tomography treated grade 1 and 2 follicular lymphoma. Leuk Lymphoma. 2007;48(8):1548–1555.
   PubMed Web of Science ®Google Scholar
• Dupuis J, Berriolo-Riedinger A, Julian A, et al. Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the groupe d‘Etudes des lymphomes de l‘Adulte and GOELAMS. J Clin Oncol. 2012;30(35):4317–4322.
   PubMed Web of Science ®Google Scholar
• Lu Z, Lin M, Downe P, et al. The prognostic value of mid- and post-treatment [(18)F]fluorodeoxyglucose (FDG) positron emission tomography (PET) in indolent follicular lymphoma. Ann Nucl Med. 2014;28(8):805–811.
   PubMed Web of Science ®Google Scholar
• Adams HJA, Kwee TC. An evidence-based review on the value of interim FDG-PET in assessing response to therapy in lymphoma. Semin Oncol. 2017;44(6):404–419.
   PubMed Web of Science ®Google Scholar
• Manji F, Bhella S, Kridel R, et al. Clinical utility of interim CT scans in patients receiving chemoimmuntherapy for first line treatment of follicular lymphoma. Leukemia and Lymphoma. 2022;14:1–7.
   PubMed Web of Science ®Google Scholar
• Liang JH, Zhang YP, Xia J, et al. Prognostic value of baseline and interim total metabolic tumor volume and total lesion glycolysis measured on 18F-FDG PET-CT in patients with follicular lymphoma. Cancer Res Treat. 2019;51(4):1479–1487.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Zhao Z, Li J, et al. Prognostic values of baseline, interim and end-of therapy (18)F-FDG PET/CT in patients with follicular lymphoma. Cancer Manag Res. 2019;11:6871–6885.
   PubMed Web of Science ®Google Scholar
• Luminari S, Manni M, Galimberti S, Fondazione Italiana Linfomi, et al. Response-Adapted postinduction strategy in patients with Advanced-Stage follicular lymphoma: the FOLL12 study. J Clin Oncol. 2022;40(7):729–739.
   PubMed Web of Science ®Google Scholar